CUDC-101: Phase Ib started

Curis began an open-label, U.S. Phase Ib trial in 40 patients to evaluate 275 mg/m 2 IV CUDC-101 given either on a 5 days per week schedule (1 week on/1 week off) or a 3 times per week schedule (3 wee...